【摘要】 市场势力的估计长期困扰着产业组织领域的研究。以中国化学药品制剂企业为例,基于KBL模型对企业市场势力及其影响因素的研究发现:第一,中国化学药品制剂企业的勒纳指数略高于0.3,意味着企业拥有市场势力,这是导致中国药品价格高企的一个重要原因;第二,广告支出强度大、创新能力强的大型制药企业有更高的市场势力。该研究结果为中国医药价格管制政策的制定提供了经验证据:一方面,从动态的角度来看,政府应健全创新支持体系,创造条件推动内资企业、中小型企业、出口型企业通过加强创新而提高竞争力,以长期促进社会福利的改善;另一方面,市场势力的存在推高了当前的药品价格,应重点对大型制药企业与公立医院之间可能存在的合谋行为进行管制。更多还原

【Abstract】 Market power estimation has long baffled researchers in the study of industrial organization. This paper uses the KBL model to estimate the market power and its determinants of China’s chemical drug industry. The main conclusions are as follows:( 1) The average Lerner index of the firms is slightly above 0. 3,which means that the enterprises have significant market power,which,in turn,is one of the important causes behind high drug prices;( 2) firms that are higher in advertising expenditure and more capable of innovation possess greater market power. Our results provide some empirical evidence for China’s policy-making for medicine pricing. It is argued that,on the one hand,from a dynamic point of view,the government should build up an innovation-supporting system to promote and encourage domestic enterprises,small and medium-sized enterprises,and export-oriented enterprises to enhance their competitiveness by stepping up innovation thereby improving social welfare in the long term. On the other hand,since enterprises’ market power pushes up drug prices,the government should focus on preventing and controlling possible collusions between public hospitals and large pharmaceutical companies.更多还原